History and Discovery
Immunoglobulins, also known as antibodies, are gamma globulin proteins that are produced by plasma cells in the immune system in response to antigens. The discovery and early research on antibodies dates back to the late 1890s when Emil von Behring and Shibasaburo Kitasato conducted experiments on diphtheria and tetanus and demonstrated that immunity could be transferred between animals using antiserum. In the 1930s, the antibodies were identified as proteins and named "immunoglobulins" based on their function of responding to foreign substances in the body. The five major classes are IgG, IgA, IgM, IgD, and IgE which differ in structure, function, and distribution in the body.
Therapeutic Uses and Growing Demand
They have found significant therapeutic applications in recent decades, especially intravenous Immunoglobulin (IVIG). IVIG is made from pools of plasma donated by thousands of healthy individuals. It is primarily used to treat primary immunodeficiencies by supplementing or replacing absent antibodies. IVIG is also used in autoimmune and inflammatory conditions such as immune thrombocytopenic purpura, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barré syndrome. The growing understanding and recognition of its clinical benefits have led to a substantial increase in IVIG usage worldwide. According to recent reports, the global IVIG was valued at over $12 billion in 2020 and is projected to grow at a CAGR of 6-7% through 2027. The widespread off-label usage of IVIG for various neurological and rheumatological conditions is further fueling this growth.
Supply Chain Challenges
While the demand for immunoglobulins is rising steadily, ensuring a continuous supply remains a challenge for Immunoglobulin manufacturers due to the dependence on human plasma as the key raw material. Only 1% of plasma collected globally can be manufactured into IVIG products. Severe plasma shortages necessitate import restrictions, voluntary collection reductions, and prioritization of orders among customers. These factors disrupt supply chains, lead to price volatility, and shortages. Companies are investing heavily in plasma collection centers and public-private partnerships to increase global plasma collection capacity. However, collecting enough high-quality plasma with the required anti-respiratory syncytial virus (RSV) titers levels poses technical difficulties. New fractionation technologies and production efficiencies are also being developed to improve yields from available plasma units.
Opportunities in Emerging
Competition is intense among leading IVIG suppliers such as Takeda, CSL Behring, Grifols, and Kedrion as they look to expand into emerging s. The Asia Pacific region represents one of the most attractive opportunities with growing healthcare investments, prevalence of immunodeficiency disorders, and increasing adoption of IVIG therapy. However, pricing pressures, import barriers and lack of adequate healthcare infrastructure pose challenges in these s. Suppliers are partnering with local plasma collection firms and distributors and registering new immunoglobulin products to gain shares. They also provide support to build cold chain logistics, train medical professionals and increase patient awareness. These efforts aim to establish early dominance before domestic manufacturers emerge as strong competitors in the coming decade.
New Formulations and Indications
While the traditional IVIG formulations dominate the currently, new subcutaneous immunoglobulin (SCIG) products have been developed to provide more convenience through weekly self-administration. Leading brands like Hizentra and Cuvitru offer SCIG options. Research is also ongoing to develop nasal sprays, ointments or orally administered them to reduce injection-related issues. Monoclonal antibody therapies present another exciting alternative; however, they only target specific antigens unlike IVIG which maintains a broad range of antibody specificities. In future, new clinical evidence may expand current IVIG usage to autoimmune neurological conditions like multiple sclerosis and myasthenia gravis. Wider adoption of IgA and IgM products could open up additional opportunities. Overall, continued innovation in formulations and exploration of therapeutic potential will drive sustained growth in the globally.
The global holds tremendous potential driven by widening clinical applications and growing patient populations worldwide. While plasma collection challenges and supply disruptions need to be addressed, ongoing efforts in capacity expansion, emerging expansion and new product developments are expected to meet the rising demand in the long run. Continuous research in immunology will further uncover the therapeutic roles of immunoglobulins, expanding treatment opportunities and values in the years ahead.
Get more insights on- Immunoglobulin
Explore More Related Article On- Immunotherapy Drugs Market
For Deeper Insights, Find the Report in the Language that You want.
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)_
